«The sale of the PRV provides an important source of non-dilutive capital to support the rapid advancement of our
follow on exon skipping candidates and next generation RNA targeted antisense
platform,» he said in a statement, referring to the action
mechanism used by the company's therapies.
The
platform follows a five - step multi-dimensional career assessment battery, which has an algorithm - driven, semi-automated career planner, tracker, and course correction
mechanism.